Cancer metabolism: Key players in metabolic reprogramming

Cancer Science

Volumn 104, Issue 3, 2013, Pages 275-281

  Soga, Tomoyoshi ^a  

^a KEIO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXYGLUTARIC ACID; 2 OXOGLUTARIC ACID; GLUTAMINASE; HYPOXIA INDUCIBLE FACTOR 1; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; PROTEIN P53; PYRUVATE KINASE; TRANSCRIPTION FACTOR;

CANCER RISK; CELL METABOLISM; ENZYME ACTIVITY; GENE MUTATION; HUMAN; MOLECULAR BIOLOGY; ONCOGENE C MYC; PRIORITY JOURNAL; REVIEW;

BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CELL TRANSFORMATION, NEOPLASTIC; FUMARATES; GENES, P53; GLUTAMINASE; GLYCOLYSIS; HUMANS; ISOCITRATE DEHYDROGENASE; MUTATION; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MYC; PYRUVATE KINASE;

EID: 84874462054     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12085     Document Type: Review

References (78)

1. Warburg O, Posener K, Negelein F. Uber den stoffwechsel der carcinomzelle. Biochem Z 1924; 152: 319-44.
2. Warburg O. On the origin of cancer cells. Biochem Z 1956; 123: 309-14.
3. Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat Rev Cancer 2011; 11: 85-95.
4. Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature 2009; 458: 719-24.
5. The International Cancer Genome Consortium. International network of cancer genome projects. Nature 2010; 464: 993-8.
6. Parsons DW, Jones S, Zhang X et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008; 321: 1807-12.
7. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009; 324: 1029-33.
8. Pedersen PL. Tumor mitochondria and the bioenergetics of cancer cells. Prog Exp Tumor Res 1978; 22: 190-274.
9. Bustamante E, Pedersen PL. High aerobic glycolysis of rat hepatoma cells in culture: role of mitochondrial hexokinase. Proc Natl Acad Sci U S A 1977; 74: 3735-9.
10. Bustamante E, Morris HP, Pedersen PL. Energy metabolism of tumor cells. Requirement for a form of hexokinase with a propensity for mitochondrial binding. J Biol Chem 1981; 256: 8699-704.
11. Hirayama A, Kami K, Sugimoto M et al. Quantitative metabolome profiling of colon and stomach cancer microenvironment by capillary electrophoresis time-of-flight mass spectrometry. Cancer Res 2009; 69: 4918-25.
12. Soga T, Ohashi Y, Ueno Y, Naraoka H, Tomita M, Nishioka T. Quantitative metabolome analysis using capillary electrophoresis mass spectrometry. J Proteome Res 2003; 2: 488-94.
13. Soga T, Baran R, Suematsu M et al. Differential metabolomics reveals ophthalmic acid as an oxidative stress biomarker indicating hepatic glutathione consumption. J Biol Chem 2006; 281: 16768-76.
14. Ward PS, Thompson CB. Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate. Cancer Cell 2012; 21: 297-308.
15. Yeung SJ, Pan J, Lee MH. Roles of p53, MYC and HIF-1 in regulating glycolysis - the seventh hallmark of cancer. Cell Mol Life Sci 2008; 65: 3981-99.
16. Wiesener MS, Jurgensen JS, Rosenberger C et al. Widespread hypoxia-inducible expression of HIF-2alpha in distinct cell populations of different organs. FASEB J 2003; 17: 271-3.
17. Schofield CJ, Ratcliffe PJ. Oxygen sensing by HIF hydroxylases. Nat Rev Mol Cell Biol 2004; 5: 343-54.
18. Semenza GL. HIF-1 and human disease: one highly involved factor. Genes Dev 2000; 14: 1983-91.
19. Semenza GL. Hypoxia, clonal selection, and the role of HIF-1 in tumor progression. Crit Rev Biochem Mol Biol 2000; 35: 71-103.
20. Maxwell PH, Pugh CW, Ratcliffe PJ. Activation of the HIF pathway in cancer. Curr Opin Genet Dev 2001; 11: 293-9.
21. Semenza GL. Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol Sci 2012; 33: 207-14.
22. Gordan JD, Thompson CB, Simon MC. HIF and c-Myc: sibling rivals for control of cancer cell metabolism and proliferation. Cancer Cell 2007; 12: 108-13.
23. Brahimi-Horn C, Berra E, Pouyssegur J. Hypoxia: the tumor's gateway to progression along the angiogenic pathway. Trends Cell Biol 2001; 11: S32-6.
24. Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res 1989; 49: 6449-65.
25. Vaupel P, Thews O, Kelleher DK, Konerding MA. O(2) extraction is a key parameter determining the oxygenation status of malignant tumors and normal tissues. Int J Oncol 2003; 22: 795-8.
26. Ohh M. Ubiquitin pathway in VHL cancer syndrome. Neoplasia 2006; 8: 623-9.
27. Gottlieb E, Tomlinson IP. Mitochondrial tumour suppressors: a genetic and biochemical update. Nat Rev Cancer 2005; 5: 857-66.
28. Pollard PJ, Ratcliffe PJ. Cancer. Puzzling patterns of predisposition. Science 2009; 324: 192-4.
29. King A, Selak MA, Gottlieb E. Succinate dehydrogenase and fumarate hydratase: linking mitochondrial dysfunction and cancer. Oncogene 2006; 25: 4675-82.
30. Pollard PJ, Brière JJ, Alam NA et al. Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations. Hum Mol Genet 2005; 14: 2231-9.
31. Kim JW, Tchernyshyov I, Semenza GL et al. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab 2006; 3: 177-85.
32. Le A, Cooper CR, Gouw AM et al. Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc Natl Acad Sci U S A 2010; 107: 2037-42.
33. Blackwood EM, Kretzner L, Eisenman RN. Myc and Max function as a nucleoprotein complex. Curr Opin Genet Dev 1992; 2: 227-35.
34. Meichle A, Philipp A, Eilers M. The functions of Myc proteins. Biochim Biophys Acta 1992; 1114: 129-46.
35. Prendergast GC, Ziff EB. A new bind for Myc. Trends Genet 1992; 8: 91-6.
36. Osthus RC, Shim H, Kim S et al. Deregulation of glucose transporter 1 and glycolytic gene expression by c-Myc. J Biol Chem 2000; 275: 21797-800.
37. Shim H, Dolde C, Lewis BC et al. c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. Proc Natl Acad Sci U S A 1997; 94: 6658-63.
38. Coller HA, Grandori C, Tamayo P et al. Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion. Proc Natl Acad Sci U S A 2000; 97: 3260-5.
39. O'Connell BC, Cheung AF, Simkevich CP et al. A large scale genetic analysis of c-Myc-regulated gene expression patterns. J Biol Chem 2003; 278: 12563-73.
40. Dang CV, Kim JW, Gao P, Yustein J. The interplay between MYC and HIF in cancer. Nat Rev Cancer 2008; 8: 51-6.
41. Vousden KH, Ryan KM. p53 and metabolism. Nat Rev Cancer 2009; 9: 691-700.
42. Schwartzenberg-Bar-Yoseph F, Armoni M, Karnieli E. The tumor suppressor p53 down-regulates glucose transporters GLUT1 and GLUT4 gene expression. Cancer Res 2004; 64: 2627-33.
43. Kondoh H, Lleonart ME, Gil J et al. Glycolytic enzymes can modulate cellular life span. Cancer Res 2005; 65: 177-85.
44. Kawauchi K, Araki K, Tobiume K, Tanaka N. p53 regulates glucose metabolism through an IKK-NF-kappaB pathway and inhibits cell transformation. Nat Cell Biol 2008; 10: 611-8.
45. Pilkis SJ, El-Maghrabi MR, Pilkis J, Claus TH. Fructose 2, 6-bisphosphate. A new activator of phosphofructokinase. J Biol Chem 1981; 256: 3171-4.
46. Hu W, Zhang C, Wu R, Sun Y, Levine A, Feng Z. Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function. Proc Natl Acad Sci U S A 2010; 107: 7455-60.
47. Suzuki S, Tanaka T, Poyurovsky MV et al. Phosphate-activated glutaminase (GLS2), a p53-inducible regulator of glutamine metabolism and reactive oxygen species. Proc Natl Acad Sci U S A 2010; 107: 7461-6.
48. Johnson RF, Perkins ND. Nuclear factor-kappaB, p53, and mitochondria: regulation of cellular metabolism and the Warburg effect. Trends Biochem Sci 2012; 37: 317-24.
49. Levine AJ, Puzio-Kuter AM. The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science 2010; 330: 1340-4.
50. van Berkel TJ, De Jonge HR, Koster JF, Hulsmann WC. Kinetic evidence for the presence of two forms of M2-type pyruvate kinase in rat small intestine. Biochem Biophys Res Commun 1974; 60: 398-405.
51. Christofk HR, Vander Heiden MG, Harris MH et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 2008; 452: 230-3.
52. Ye J, Mancuso A, Tong X et al. Pyruvate kinase M2 promotes de novo serine synthesis to sustain mTORC1 activity and cell proliferation. Proc Natl Acad Sci U S A 2012; 109: 6904-9.
53. Hitosugi T, Kang S, Vander Heiden MG et al. Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth. Sci Signal 2009; 2: ra73.
54. Anastasiou D, Poulogiannis G, Asara JM et al. Inhibition of pyruvate kinase M2 by reactive oxygen species contributes to cellular antioxidant responses. Science 2011; 334: 1278-83.
55. Gruning NM, Rinnerthaler M, Bluemlein K et al. Pyruvate kinase triggers a metabolic feedback loop that controls redox metabolism in respiring cells. Cell Metab 2011; 14: 415-27.
56. Gruning NM, Ralser M. Cancer: sacrifice for survival. Nature 2011; 480: 190-1.
57. Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol 2008; 116: 597-602.
58. Watanabe T, Nobusawa S, Kleihues P, Ohgaki H. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 2009; 174: 1149-53.
59. Yan H, Parsons DW, Jin G et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009; 360: 765-73.
60. Dang L, White DW, Gross S et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009; 462: 739-44.
61. Dang L, Jin S, Su SM. IDH mutations in glioma and acute myeloid leukemia. Trends Mol Med 2010; 16: 387-97.
62. Lu C, Ward PS, Kapoor GS et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 2012; 483: 474-8.
63. Figueroa ME, Abdel-Wahab O, Lu C et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010; 18: 553-67.
64. Guo JU, Su Y, Zhong C, Ming GL, Song H. Hydroxylation of 5-methylcytosine by TET1 promotes active DNA demethylation in the adult brain. Cell 2011; 145: 423-34.
65. Santos CR, Schulze A. Lipid metabolism in cancer. FEBS J 2012; 279: 2610-23.
66. Wise DR, Ward PS, Shay JE et al. Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of alpha-ketoglutarate to citrate to support cell growth and viability. Proc Natl Acad Sci U S A 2011; 108: 19611-6.
67. Metallo CM, Gameiro PA, Bell EL et al. Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. Nature 2012; 481: 380-4.
68. Wakil SJ. Fatty acid synthase, a proficient multifunctional enzyme. Biochemistry 1989; 28: 4523-30.
69. Hatzivassiliou G, Zhao F, Bauer DE et al. ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell 2005; 8: 311-21.
70. Wellen KE, Hatzivassiliou G, Sachdeva UM, Bui TV, Cross JR, Thompson CB. ATP-citrate lyase links cellular metabolism to histone acetylation. Science 2009; 324: 1076-80.
71. Reitzer LJ, Wice BM, Kennell D. Evidence that glutamine, not sugar, is the major energy source for cultured HeLa cells. J Biol Chem 1979; 254: 2669-76.
72. Gallagher FA, Kettunen MI, Day SE, Lerche M, Brindle KM. 13C MR spectroscopy measurements of glutaminase activity in human hepatocellular carcinoma cells using hyperpolarized 13C-labeled glutamine. Magn Reson Med 2008; 60: 253-7.
73. Gao P, Tchernyshyov I, Chang TC et al. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature 2009; 458: 762-5.
74. Sakai C, Tomitsuka E, Esumi H, Harada S, Kita K. Mitochondrial fumarate reductase as a target of chemotherapy: from parasites to cancer cells. Biochim Biophys Acta 2012; 1820: 643-51.
75. Tomitsuka E, Kita K, Esumi H. The NADH-fumarate reductase system, a novel mitochondrial energy metabolism, is a new target for anticancer therapy in tumor microenvironments. Ann N Y Acad Sci 2010; 1201: 44-9.
76. Kita K, Takamiya S. Electron-transfer complexes in Ascaris mitochondria. Adv Parasitol 2002; 51: 95-131.
77. Groves AM, Win T, Haim SB, Ell PJ. Non-[18F]FDG PET in clinical oncology. Lancet Oncol 2007; 8: 822-30.
78. Vander Heiden MG. Targeting cancer metabolism: a therapeutic window opens. Nat Rev Drug Discov 2011; 10: 671-84.